The pentavalent rotavirus vaccine, RotaTeq

Semin Pediatr Infect Dis. 2006 Oct;17(4):195-9. doi: 10.1053/j.spid.2006.08.005.

Abstract

Vaccination against rotavirus disease has been a global preventive health priority since rotaviruses were first discovered in the 1970s. The first licensed rotavirus vaccine, RRV-TV, was removed from the market shortly after licensure because of an unexpected serious adverse event, intussusception. A pentavalent rotavirus vaccine, PRV, is the second FDA-licensed rotavirus vaccine and does not signal the risk observed with RRV-TV. The properties and large safety study results of PRV are reviewed here.

Publication types

  • Review

MeSH terms

  • Diarrhea, Infantile / immunology
  • Diarrhea, Infantile / prevention & control
  • Diarrhea, Infantile / virology
  • Drug-Related Side Effects and Adverse Reactions
  • Humans
  • Immunization / methods*
  • Infant
  • Intussusception
  • Rotavirus / immunology*
  • Rotavirus Infections / immunology
  • Rotavirus Infections / prevention & control*
  • Rotavirus Infections / virology
  • Rotavirus Vaccines / adverse effects
  • Rotavirus Vaccines / immunology
  • Rotavirus Vaccines / therapeutic use*
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / immunology
  • Vaccines, Attenuated / therapeutic use*

Substances

  • RotaTeq
  • Rotavirus Vaccines
  • Vaccines, Attenuated